Waddell & Reed Financial’s Pacira BioSciences PCRX Stock Holding History

Waddell & Reed Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$9.1M	Buy	+129,880	New	+$9.28M	0.02%	409
2017 Q4	–	Sell	-815,666	Closed	-$30.6M	–	549
2017 Q3	$30.6M	Buy	815,666 +100	+0%	+$4.02K	0.07%	286
2017 Q2	$38.9M	Buy	815,566 +89,915	+12%	+$4.17M	0.09%	261
2017 Q1	$33.1M	Buy	725,651 +163,971	+29%	+$7.09M	0.07%	287
2016 Q4	$18.1M	Buy	+561,680	New	+$18.7M	0.04%	350

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Waddell & Reed Financial's PCRX Position: Q1 2021 in Review

Waddell & Reed Financial opened a new position in Pacira BioSciences (PCRX) in Q1 2021: 129,880 shares worth $9.1M. The stake represents 0.02% of the portfolio and ranks #409 among its holdings. This is a return to the name: Waddell & Reed Financial previously reported a position in PCRX as recently as Q3 2017.

Waddell & Reed Financial first reported a position in PCRX in Q4 2016 and has held it in 5 quarters since. The position peaked at $38.9M in Q2 2017. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

Waddell & Reed Financial held 129,880 shares of Pacira BioSciences worth $9.1M as of Q1 2021.
Pacira BioSciences was a new Waddell & Reed Financial position in Q1 2021.
Pacira BioSciences made up 0.02% of Waddell & Reed Financial's portfolio in Q1 2021, its #409 holding.
Waddell & Reed Financial first reported a position in Pacira BioSciences in Q4 2016 and has held it in 5 quarters since.
Waddell & Reed Financial's Pacira BioSciences position peaked at $38.9M in Q2 2017.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.